FDA Approval Alert: The Need-to-Know | Nilotinib Tablets in Ph+ CML in Chronic Phase

In November 2024, the FDA approved nilotinib tablets, without mealtime restrictions, for patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia.

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.
Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase
Article
Nov 14, 2024 9:29 PM
Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.